Traders should monitor upcoming topline data from the ZEPHYR and IRIS trials in Q3 2026, which could serve as major catalysts. Despite rising losses, the strong cash position reduces near-term dilution risk.
Price Chart
Executive Summary
MapLight Therapeutics reported financial results for Q4 and full year 2025, highlighting a significant increase in R&D and G&A expenses leading to a larger net loss, while maintaining a strong cash position of $453.1 million that funds operations through 2027. The company provided updates on its clinical pipeline, including expected topline data from Phase 2 trials for schizophrenia and autism in Q3 2026, and received FDA Fast Track designation for ML-007C-MA in Alzheimer’s disease psychosis.
Key Financial Metrics
Key Facts
- Cash, cash equivalents, and investments totaled $453.1 million as of December 31, 2025, up from $120.2 million in 2024.
- R&D expenses were $64.6 million in Q4 2025 vs. $20.7 million in Q4 2024; full-year R&D increased to $138.3 million from $68.5 million.
- G&A expenses rose to $18.8 million in Q4 2025 from $2.1 million in the prior year period.
- Net loss was $79.5 million in Q4 2025 vs. $21.2 million in Q4 2024; full-year net loss was $161.2 million vs. $77.6 million in 2024.
- Phase 2 ZEPHYR (schizophrenia) and IRIS (autism) trials expected to report topline results in Q3 2026; VISTA trial (ADP) results expected in H2 2027.
- FDA granted Fast Track designation for ML-007C-MA for Alzheimer’s disease psychosis in December 2025.
- ML-055, a next-generation M1/M4 agonist, is on track for candidate nomination in 2026.
Financial Impact
Increased R&D and G&A spending drove net loss to $161.2 million in 2025, more than double the $77.6 million loss in 2024, but cash reserves remain strong at $453.1 million.
Risk Factors
- Clinical trial results may not meet expectations, particularly given the high failure rate in CNS drug development.
- Increased operating expenses may pressure margins and require future capital raises if development timelines extend.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262855 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | Insider Cluster | $8.00 | awaiting T+20 | — | $7.66 (+4.25%) |
Oct 15, 2026 11d ago | 144 | $7.70 | awaiting T+20 | — | $7.66 (−0.52%) |
Oct 15, 2026 11d ago | 144 | $7.70 | awaiting T+20 | — | $7.66 (−0.52%) |
Oct 15, 2026 11d ago | 144 | $7.70 | awaiting T+20 | — | $7.66 (−0.52%) |
Sep 24, 2026 4w ago | EFFECT | $10.76 $8.25 | ▼ −23.33% | ▼ −22.91% | $7.66 (−28.81%) |
Sep 18, 2026 5w ago | S-1/A | $10.90 $8.00 | ▼ −26.61% | ▼ −25.70% | $7.66 (−29.72%) |
Aug 4, 2026 11w ago | Insider Cluster | $12.92 $13.06 | ▲ +1.08% | ▲ +1.69% | $7.66 (−40.71%) |
Aug 3, 2026 12w ago | 144 | $12.94 $13.31 | ▲ +2.86% | ▲ +4.10% | $7.66 (−40.80%) |
Jul 30, 2026 12w ago | 144 | $13.02 $12.60 | ▲ +3.23% | ▲ +6.21% | $7.66 (+41.17%) |
Jul 28, 2026 12w ago | Insider Buy | $15.02 $12.86 | ▼ −14.38% | ▼ −19.40% | $7.66 (−49.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers